Meningococcal Meningitis Clinical Trial
— ETH-TVTOfficial title:
A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians
Primary objective:
To assess the immunogenicity of the Mencevax ACW135 polysaccharide vaccine at 28 days
(+6days) post vaccination in 2-4, 5-14, 15-29 year age groups and compare the immunogenicity
between these age groups.
Secondary Objectives:
- To estimate the incidence of common adverse events following immunization (AEFI) of GSK
Nm ACW135 polysaccharide vaccine at 1h, 1d, 2d, 3d, 7d and 28 days post-vaccination
- To assess the persistence of antibody against meningitis A, C and W135 at 11 and 23
months post vaccination in 2-4, 5-14, 15-29 year age groups
Study site:Two rural communities (Kebele) in Butajira district, Ethiopia.
Methods:
- Phase II, open and parallel safety and immunogenicity trial.
- 234 younger children (2-4 years), 145 older children (5-14 years) and 33 adults (15-29
years of age) were randomly selected from the demographic surveillance database and
enrolled after screening and consenting.
- Study participant received Mencevax ACW polysaccharide vaccine 50 mg in 0.5ml
subcutaneously.
- Blood samples for measuring SBA titres were collected at pre vaccination and on day 28
(+6 days) post vaccination.
- Active follow up for AEFI on post vaccination day 0, 1, 2, 3, 7, & 28.
- Primary end point was vaccine response defined as sero-conversion (in subjects
initially seronegative) or a 4 fold increase (in subjects initially seropositive) in
serum bactericidal antibodies (SBA) against serogroups Men A, C and W135) on post
vaccination day 28. In addition seroconversion was assessed by ELISA Men A IgG on day 0
and day 28 post vaccination.
- Secondary endpoints were incidence of general and local symptoms and other adverse
events following immunisation during the post vaccination period day 0 to 28 and immune
persistence on post vaccination month-11 and month-23.
Results:
- No significant difference in the incidence of general or local AEFI was observed
between the age groups
- The statistical analysis for the Immunogenicity data is in progress
Status | Completed |
Enrollment | 412 |
Est. completion date | November 2007 |
Est. primary completion date | January 2006 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 2 Years to 29 Years |
Eligibility |
Inclusion Criteria: 1. Age between 2-29 years, both sexes, living in the selected villages of Butajira area 2. A written informed consent signed by the individual (>=18y) or caretaker/guardian (2 to 17 years of age) as 18 is the legal age of maturity in Ethiopia. Assent from children/adolescents aged 12-17 years old. 3. Free of obvious health problems ascertained by medical history and clinical examination on the day of enrolment Exclusion Criteria: 1. Those who are unlikely to complete the follow up at 4-weeks post-vaccination. 2. Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period. 3. Administration of blood transfusion within 2 years prior to enrolment or planned use during the study period. 4. Verbal report of previous vaccination with meningococcal serogroup A, C, Y or W135 vaccines since 1999. 5. Confirmed or suspected immunosuppressive or immunodeficient condition including HIV infection. 6. A family history of congenital or hereditary immunodeficiency. 7. History of allergic reaction to any component of the vaccine 8. Presence of any fever (defined as axillary temperature of 37.5 degree centigrade or more) and/or severe illness on the day of enrolment/ vaccination. 9. Pregnancy. 10. lactation |
Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Ethiopia | Butajira Hospital | Butajira | Southern Nationality |
Lead Sponsor | Collaborator |
---|---|
Armauer Hansen Research Institute, Ethiopia | Addis Ababa University, LSHTM,UK, World Health Organization |
Ethiopia,
Aseffa A, Bedru A, Yamuah L, Arga D, Worku A, Chandramohan D, Nelson CB, Engers HD. Safety of a trivalent meningococcal ACW135 vaccine among young children in Ethiopia. Vaccine. 2007 Sep 3;25 Suppl 1:A79-82. Epub 2007 May 4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate point estimates and trends in immunogenicity after not less than 28 days (+6 days) among children 2 - 4 years as compared to children 5 - 14 years and adolescents/adults 15 - 29 years (all ages inclusive) | 28 days | No | |
Secondary | To assess the incidence of adverse events following vaccination at 1h, 1d, 2d, 3d, 7d and 28 days post-vaccination. | 28days | Yes | |
Secondary | To assess the immunogenicity at 11 months and 23 months (inclusive) postvaccination. | 23 month | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01434680 -
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
|
Phase 2 | |
Completed |
NCT01424644 -
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
|
Phase 4 | |
Completed |
NCT00384397 -
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT01453348 -
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT01214837 -
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
|
Phase 3 | |
Completed |
NCT00874549 -
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
|
Phase 1/Phase 2 | |
Completed |
NCT00355121 -
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
|
Phase 2 | |
Completed |
NCT02591290 -
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
|
Phase 4 | |
Completed |
NCT01717638 -
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
|
Phase 3 | |
Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
Completed |
NCT01482052 -
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
|
Phase 1 | |
Completed |
NCT01239043 -
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
|
Phase 2 | |
Completed |
NCT01732627 -
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
|
Phase 2 | |
Completed |
NCT01478347 -
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
|
Phase 3 | |
Completed |
NCT00483574 -
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
|
Phase 3 | |
Completed |
NCT00474487 -
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
|
Phase 3 | |
Completed |
NCT03205358 -
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers
|
Phase 2 | |
Not yet recruiting |
NCT06226714 -
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds
|
Phase 3 | |
Completed |
NCT00667602 -
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers
|
Phase 3 | |
Completed |
NCT00450437 -
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
|
Phase 3 |